Literature DB >> 20463113

The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease.

Roseanne DeFronzo Dobkin1, Matthew Menza, Karina L Bienfait, Michael Gara, Humberto Marin, Margery H Mark, Allison Dicke, Alexander Tröster.   

Abstract

Depression is associated with more rapid cognitive decline in Parkinson's disease. The goal of this study was to examine the impact of the acute (8-week) and longer-term (24-week) antidepressant treatment on cognition in Parkinson's disease and to detail cognitive predictors of treatment response. Fifty-two depressed Parkinson's disease patients were enrolled in an NIH-funded randomized, controlled trial of nortriptyline, paroxetine, and placebo. Neuropsychological testing was performed at baseline and weeks 8 and 24. Higher baseline scores on measures of executive functioning, speed of processing, and verbal memory were associated with antidepressant response. Treatment responders did not exhibit larger gains in cognition than nonresponders. Findings warrant replication.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20463113      PMCID: PMC2872099          DOI: 10.1176/jnp.2010.22.2.188

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  30 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Changes in cognitive functioning following treatment of late-life depression.

Authors:  M A Butters; J T Becker; R D Nebes; M D Zmuda; B H Mulsant; B G Pollock; C F Reynolds
Journal:  Am J Psychiatry       Date:  2000-12       Impact factor: 18.112

3.  The assessment of anxiety states by rating.

Authors:  M HAMILTON
Journal:  Br J Med Psychol       Date:  1959

4.  Research diagnostic criteria for Parkinson's disease.

Authors:  C D Ward; W R Gibb
Journal:  Adv Neurol       Date:  1990

5.  Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study.

Authors:  Daniel Weintraub; Donna Taraborelli; Knashawn H Morales; John E Duda; Ira R Katz; Matthew B Stern
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2006       Impact factor: 2.198

6.  Dimensions of executive function in Parkinson's disease.

Authors:  Daniel Weintraub; Paul J Moberg; William C Culbertson; John E Duda; Ira R Katz; Matthew B Stern
Journal:  Dement Geriatr Cogn Disord       Date:  2005-07-13       Impact factor: 2.959

7.  Residual cognitive impairment in late-life depression after a 12-month period follow-up.

Authors:  M J Portella; T Marcos; L Rami; V Navarro; C Gastó; M Salamero
Journal:  Int J Geriatr Psychiatry       Date:  2003-07       Impact factor: 3.485

8.  Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine.

Authors:  Robert D Nebes; Bruce G Pollock; Patricia R Houck; Meryl A Butters; Benoit H Mulsant; Michelle D Zmuda; Charles F Reynolds
Journal:  J Psychiatr Res       Date:  2003 Mar-Apr       Impact factor: 4.791

9.  Treatment response in late-onset depression: relationship to neuropsychological, neuroradiological and vascular risk factors.

Authors:  R Baldwin; S Jeffries; A Jackson; C Sutcliffe; N Thacker; M Scott; A Burns
Journal:  Psychol Med       Date:  2004-01       Impact factor: 7.723

10.  The influence of depression on cognition in Parkinson's disease: a pattern of impairment distinguishable from Alzheimer's disease.

Authors:  A I Tröster; A M Paolo; K E Lyons; S L Glatt; J P Hubble; W C Koller
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

View more
  15 in total

1.  Predictors of treatment response to cognitive-behavioral therapy for depression in Parkinson's disease.

Authors:  Roseanne D Dobkin; Jade Tiu Rubino; Lesley A Allen; Jill Friedman; Michael A Gara; Margery H Mark; Matthew Menza
Journal:  J Consult Clin Psychol       Date:  2012-03-12

2.  Dopaminergic modulation of memory and affective processing in Parkinson depression.

Authors:  Lee X Blonder; John T Slevin; Richard J Kryscio; Catherine A Martin; Anders H Andersen; Charles D Smith; Frederick A Schmitt
Journal:  Psychiatry Res       Date:  2013-07-06       Impact factor: 3.222

3.  Neuropsychological outcomes after psychosocial intervention for depression in Parkinson's disease.

Authors:  Roseanne D Dobkin; Alexander I Tröster; Jade Tiu Rubino; Lesley A Allen; Michael A Gara; Margery H Mark; Matthew Menza
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2014       Impact factor: 2.198

Review 4.  The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review.

Authors:  Albert F G Leentjens
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

Review 5.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 6.  Psychiatric issues in cognitive impairment.

Authors:  Dag Aarsland; John-Paul Taylor; Daniel Weintraub
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 7.  Depression in Parkinson disease--epidemiology, mechanisms and management.

Authors:  Dag Aarsland; Sven Påhlhagen; Clive G Ballard; Uwe Ehrt; Per Svenningsson
Journal:  Nat Rev Neurol       Date:  2011-12-26       Impact factor: 42.937

8.  Serotonin, β-amyloid, and cognition in Parkinson disease.

Authors:  Vikas Kotagal; Cathie Spino; Nicolaas I Bohnen; Robert Koeppe; Roger L Albin
Journal:  Ann Neurol       Date:  2018-05-11       Impact factor: 10.422

9.  Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management.

Authors:  Roseanne DeFronzo Dobkin; Matthew Menza; Karina L Bienfait; Michael Gara; Humberto Marin; Margery H Mark; Allison Dicke; Jill Friedman
Journal:  Am J Geriatr Psychiatry       Date:  2011-03       Impact factor: 4.105

Review 10.  Depression and Parkinson's disease: current knowledge.

Authors:  Laura Marsh
Journal:  Curr Neurol Neurosci Rep       Date:  2013-12       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.